CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionAdvisory Services Network, LLC
Latest Disclosed Ownership16,965 shares
Latest Disclosed Value $ 807,025
Advisory Services Network, LLC reports 14.29% increase in ownership of CRSP / CRISPR Therapeutics AG

On May 15, 2026 - Advisory Services Network, LLC filed a 13F-HR form disclosing ownership of 16,965 shares of CRISPR Therapeutics AG (US:CRSP) valued at $807,025 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 14,844 shares of CRISPR Therapeutics AG. This represents a change in shares of 14.29% during the quarter. The current value of the position is $966,157 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 16,965 2,121 14.29 807 3.73 0.0075
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 14,844 1,024 7.41 778 -13.07 0.0110
2025-11-18 2025-09-30 13F CRISPR THERAPEUTICS Stock H17182108 13,820 350 2.60 896 18.23 0.0131
2025-08-19 2025-06-30 13F CRISPR THERAPEUTICS Stock H17182108 13,470 3,509 35.23 758 123.96 0.0122
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS Stock H17182108 9,961 -96 -0.95 339 -14.43 0.0065
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS Stock H17182108 10,057 -7,629 -43.14 396 -58.64 0.0074
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS Stock H17182108 17,686 0 0.00 955 0.00 0.0197
2024-08-13 2024-06-30 13F CRISPR THERAPEUTICS Stock H17182108 17,686 112 0.64 955 -20.22 0.0197
2024-05-06 2024-03-31 13F CRISPR THERAPEUTICS Stock H17182108 17,574 -100 -0.57 1,198 8.23 0.0266
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS Stock H17182108 17,674 3,854 27.89 1,106 76.40 0.0270
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS Stock H17182108 13,820 -706 -4.86 627 -23.07 0.0168
2023-08-09 2023-06-30 13F CRISPR THERAPEUTICS Stock H17182108 14,526 170 1.18 815 25.58 0.0217
2023-05-17 2023-03-31 13F CRISPR THERAPEUTICS Stock H17182108 14,356 11,907 486.20 649 555.56 0.0180
2023-02-13 2022-12-31 13F CRISPR THERAPEUTICS Stock H17182108 2,449 -635 -20.59 100 -50.99 0.0031
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS Stock H17182108 3,084 -3,203 -50.95 202 -47.12 0.0071
2022-08-02 2022-06-30 13F CRISPR THERAPEUTICS Stock H17182108 6,287 -7,133 -53.15 382 -54.63 0.0131
2022-05-23 2022-03-31 13F CRISPR THERAPEUTICS Stock H17182108 13,420 1,069 8.66 842 -10.04 0.0248
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS Stock H17182108 12,351 -435 -3.40 936 -34.59 0.0269
2021-11-05 2021-09-30 13F CRISPR THERAPEUTICS Stock H17182108 12,786 337 2.71 1,431 -28.98 0.0455
2021-08-12 2021-06-30 13F CRISPR THERAPEUTICS Stock H17182108 12,449 2,291 22.55 2,015 62.76 0.0636
2021-05-24 2021-03-31 13F CRISPR THERAPEUTICS Stock H17182108 10,158 1,848 22.24 1,238 -2.67 0.0460
2021-02-09 2020-12-31 13F CRISPR THERAPEUTICS Stock H17182108 8,310 7,169 628.31 1,272 1,238.95 0.0510
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS Stock H17182108 1,141 1,141 95 0.0045
2020-08-10 2020-06-30 13F CRISPR THERAPEUTICS Stock H17182108 0 -674 -100.00 0 -100.00
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS Stock H17182108 674 0 0.00 29 -29.27 0.0019
2020-02-04 2019-12-31 13F CRISPR THERAPEUTICS Stock H17182108 674 400 145.99 41 215.38 0.0022
2019-11-04 2019-09-30 13F CRISPR THERAPEUTICS Stock H17182108 274 0 0.00 13 0.00 0.0008
2019-08-01 2019-06-30 13F CRISPR THERAPEUTICS Stock H17182108 274 200 270.27 13 333.33 0.0008
2019-05-20 2019-03-31 13F CRISPR THERAPEUTICS Stock H17182108 74 0 0.00 3 50.00 0.0002
2019-02-15 2018-12-31 13F CRISPR THERAPEUTICS Stock H17182108 74 0 0.00 2 -33.33 0.0002
2018-11-02 2018-09-30 13F CRISPR THERAPEUTICS Stock H17182108 74 0 0.00 3 -25.00 0.0002
2018-07-27 2018-06-30 13F CRISPR THERAPEUTICS Stock H17182108 74 -921 -92.56 4 -91.11 0.0003
2018-04-23 2018-03-31 13F CRISPR THERAPEUTICS Stock H17182108 995 995 45 0.0036
2018-02-08 2017-12-31 13F CRISPR THERAPEUTICS Stock H17182108 0 -100 -100.00 0 -100.00
2017-10-12 2017-09-30 13F CRISPR THERAPEUTICS Stock H17182108 100 0 0.00 2 0.00 0.0002
2017-08-17 2017-06-30 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 100 0 0.00 2 0.00 0.0003
2017-04-28 2017-03-31 13F CRISPR THERAPEUTICS AG NAMEN AKT Stock H17182108 100 100 2 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.